Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema

doi:10.1016/S0002-9394(01)01010-8

American Journal of Ophthalmology

Volume 132, Issue 3, September 2001, Pages 425-427

https://doi.org/10.1016/S0002-9394(01)01010-8 Get rights and content

Abstract

PURPOSE: To report the clinical outcome of a diabetic patient with macular edema treated with an intravitreal injection of crystalline cortisone.

METHODS: Interventional case report. A 73-year-old patient with diabetes mellitus presented with clinically significant diffuse macular edema caused by nonproliferative diabetic retinopathy. Despite grid laser coagulation in the macular region, cystoid macular edema progressed, and within 6 months before the cortisone injection, visual acuity declined from 0.25 to 0.16 and, finally, to 0.10. The patient received a single intravitreal injection of triamcinolone acetonide with topical anesthesia.

RESULTS: After the intravitreal injection of triamcinolone acetonide, visual acuity improved from 0.10 to 0.40 during the follow-up period spanning 5 months. Intraocular pressure increased to values up to 30 mm Hg before antiglaucomatous treatment.

CONCLUSION: Intravitreal injection of triamcinolone acetonide may be useful for treatment of diabetic macular edema resistant to conventional therapy.

References (5)

R.H. Schindler et al.
The clearance of intravitreal triamcinolone acetonide
Am J Ophthalmol
(1982)
J.B. Jonas et al.
Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative diabetic retinopathy
Am J Ophthalmol
(2001)

There are more references available in the full text version of this article.

Cited by (405)

Recent advances and future prospects: Current status and challenges of the intraocular injection of drugs for vitreoretinal diseases
2023, Advanced Drug Delivery Reviews
Effective drug therapy for vitreoretinal disease is a major challenge in the field of ophthalmology; various protective systems, including anatomical and physiological barriers, complicate drug delivery to precise targets. However, as the eye is a closed cavity, it is an ideal target for local administration. Various types of drug delivery systems have been investigated that take advantage of this aspect of the eye, enhancing ocular permeability and optimizing local drug concentrations. Many drugs, mainly anti-VEGF drugs, have been evaluated in clinical trials and have provided clinical benefit to many patients. In the near future, innovative drug delivery systems will be developed to avoid frequent intravitreal administration of drugs and maintain effective drug concentrations for a long period of time. Here, we review the published literature on various drugs and administration routes and current clinical applications. Recent advances in drug delivery systems are discussed along with future prospects.
Can the Future be Bright with Advances in Diabetic Eye Care?
2023, Endocrinology and Metabolism Clinics of North America
Citation Excerpt :
The development of DME is not solely dependent on VEGF release; several inflammatory cytokines are implicated in the pathogenesis of DME. Triamcinolone acetonide (TA) was evaluated in patients with DR in the early 2000s.41,42 Subsequently numerous clinical trials were conducted to evaluate its safety and efficacy compared to laser photocoagulation or anti-VEGF in patients with DME.
Introduction: An overview of the non-parenteral delivery of nanomedicine
2020, Theory and Applications of Nonparenteral Nanomedicines
Delivery of therapeutic agents to the target cells is a promising aspect of nanotechnology in biomedicine. This approach not only provides a specific treatment opportunity but also protects the neighboring healthy cells. Nonetheless, non-parenteral routes have beneficial advantages compared to parenteral routes such as simpler needleless process and better patient compliance. In this chapter, we have provided an overview of non-parenteral delivery of nanomaterials. The main focus was on technologies that have utmost pharmaceutical and commercial capabilities. Mucoadhesive systems and chitosan-based non-parenteral nano delivery systems are at core of attention in this chapter due to their importance in non-parenteral delivery of nanomedicines. The importance of vaccine delivery using non-parenteral nanosystems is also discussed in this chapter. The review process show that the most generally applied form of non-parenteral route is oral administration, which is capable of stimulating mucosal immune response in gastrointestinal tract. There are also promising advances in other non-parenteral routes including nasal, ocular, and transdermal routes for delivery of nanomaterials. Based on the reports, intranasal administration route is a favorable choice for local delivery of vaccines, and has been shown to be effective in different animal models and humans. The results of the review process also show that chitosan is almost the most important cationic polymer in nature which currently holds enormous promise for use in pharmaceutical dosage forms because of its unique features. It can be concluded that advance toward developing non-parenteral delivery systems for nanomedicine applications should be continued by investigators from different fields of biomedicine to achieve more advancing delivery systems.
The Treatment of Diabetic Retinal Edema with Intravitreal Steroids: How and When
2024, Journal of Clinical Medicine
Management of treatment-naïve diabetic macular edema patients: Review of real-world clinical data
2024, European Journal of Ophthalmology
The Evolution of Triamcinolone Acetonide Therapeutic Use in Retinal Diseases: From Off-Label Intravitreal Injection to Advanced Nano-Drug Delivery Systems
2023, Biomedicines

View all citing articles on Scopus

View full text

Brief reportIntraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema

Abstract

Am J Ophthalmol

Am J Ophthalmol

Brief report
Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema